Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
Assessment of the QT Interval Using a Smartphone ECG Device during Antiarrhythmic Drug Initiation
Rochester, Minn.
- Obtain AliveCor ECG Recordings from subjects at the time of clinically indicated ECGs over the course their anti-arrhythmic drug loading hospital admission.
- Create and refine an AliveCor algorithm to accurately measure a patient’s QT interval and heart rate corrected QTc value and validate/compare the results against the 12- lead ECGs on record.
- Obtain AliveCor ECG recordings at the time of daily clinically indicated electrolyte panels to further develop and refine a Potassium screening algorithm.
-
Genetic Predictors of QT Prolongation with Anti-arrhythmic Medication
Rochester, Minn.
The purpose of this study is to assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in patients being started on dofetilide. We will examine the predictiveness of a QT genotype score on QT prolongation in patients admitted for dofetilide initiation.
-
IQ-ECG STUDY - Improve the Quality of ElectroCardioGrams in Ventricular Assist Device Patients by Using a 20 Hz Filter to Better Assess Electrocardiogram Abnormalities (IQ-ECG)
Rochester, Minn.
The main objective of this study to assess the quality of the ECG readings between different filters from both the GE machine and the Smartheart device.
-
Screening for PEripartum Cardiomyopathies Using Artificial Intelligence (SPEC-AI) (SPEC-AI)
Rochester, Minn.,
Jacksonville, Fla.
The overall goal of this study is to investigate the use of artificial intelligence (AI) techniques as a screening tool for cardiomyopathies in pregnancy and the post-partum period.
-
The NODE-303 Study: Multi-Centre, Multi-National,Open Label, Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. (NODE-303)
Rochester, Minn.
The purpose of this study is to evaluate the safety of etripamil nasal spray in patients with Paroxysmal Supraventricular Tachycardia (PSVT). Patients will be provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS will be self-applied by the patient, when PSVT symptoms begin. Patients will self-administer etripamil NS if vagal maneuver is ineffective. After an episode of PSVT where drug is administered, the patient will return to the investigative site for a study visit and will be given the option to continue in NODE-303 and manage subsequent episodes of PSVT with etripamil NS.
Closed for Enrollment
-
Effect of Wearable Devices on Patient-Reported Outcomes and Clinical Utilization: A Randomized, Controlled Trial
Rochester, Minn.
The purpose of this study is to help researchers better understand the impact of wearable devices on patient experience and clinical trends following a cardioversion.
-
Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. The NODE-301 Trial.
Rochester, Minn.
The primary objective of this study is to determine whether etripamil nasal spray (NS) 70 mg is superior to placebo at terminating episodes of Paroxysmal Supraventricular Tachycardia (PSVT) in an outpatient setting.
-
Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. The NODE-301 Trial.
Rochester, Minn.
The primary objective of this study is to determine whether etripamil nasal spray (NS) 70 mg is superior to placebo at terminating episodes of PSVT in an outpatient setting.
-
Shared Decision Making for Stroke Prevention in Atrial Fibrillation (SDM4Afib): A Randomized Trial (SDM4Afib)
Rochester, Minn.
The objective of this project is to evaluate a treatment decision aid for patients with atrial fibrillation.
-
The Prevalence of Common Genetic Variants that Affect QT Interval among Patients with Medication-Induced Torsade de Pointes
Rochester, Minn.
The purpose of this study is to determine if common genetic variants that underlie the QT interval are also associated with medication-induced torsade de pointes (TdP).
.